Zobrazeno 1 - 10
of 388
pro vyhledávání: '"Ann S. Lacasce"'
Autor:
Alessandra Zaccardelli, Fabienne M. Lucas, Ann S. LaCasce, Anil K. Chandraker, Jamil R. Azzi, Simon G. Talbot
Publikováno v:
Frontiers in Transplantation, Vol 3 (2024)
Vascularized composite allotransplantation (VCA) is an emerging field in transplant surgery. Despite overall positive outcomes, VCA confers risk for multiple complications related to the procedure and subsequent immunosuppression. Post-transplant lym
Externí odkaz:
https://doaj.org/article/5f40cdc5cf9d413cb981f7543aad29b8
Autor:
Howland E. Crosswell, Ann S. LaCasce, Nancy L. Bartlett, David J. Straus, Kerry J. Savage, Pier Luigi Zinzani, Graham P. Collins, Michelle Fanale, Keenan Fenton, Cassie Dong, Harry Miao, Andrew P. Grigg
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/812cd0e47a2943868ab741041339d5d9
Autor:
Ann S. LaCasce
Publikováno v:
Haematologica, Vol 108, Iss 6 (2023)
Externí odkaz:
https://doaj.org/article/f7432f74dcaa401ca5237cdb0c9e7379
Autor:
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schöder, Heather Jacene
Publikováno v:
HemaSphere, Vol 7, Iss 2, p e826 (2023)
While most patients with follicular lymphoma (FL) have excellent outcomes with frontline chemoimmunotherapy (CIT), a subset of patients will experience early progression, which is associated with poor subsequent outcomes. Novel biomarkers are needed
Externí odkaz:
https://doaj.org/article/83d25c36f6aa4d008cd0ecfabeefe63a
Autor:
Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Jad Bsat, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp, Yi-Bin Chen, Robin M. Joyce
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 122-126 (2020)
Abstract: Disease relapse remains the leading cause of failure after autologous stem cell transplantation (ASCT) for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase 2, multicenter, single-arm study of
Externí odkaz:
https://doaj.org/article/6dcead3a5e7b4235ab3757f5129bfa75
Autor:
Julia Driessen, Fer De Wit, Alex F. Herrera, Pier Luigi Zinzani, Ann S. Lacasce, Peter D. Cole, Craig H. Moskowitz, Ramón. García Sanz, Michael Fuchs, Horst Müller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée. M. Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten
Publikováno v:
HemaSphere, Vol 6, Pp 49-49 (2022)
Externí odkaz:
https://doaj.org/article/944d942416844f119d5067af91baa190
Autor:
Steven P. Treon, Ann S. LaCasce, Sally Tan, Anna K. Dewan, Matthew S. Davids, Nicole R. LeBoeuf, Sean Singer
Publikováno v:
Journal of the American Academy of Dermatology. 88:1271-1281
Background Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK) that is FDA-approved for several lymphoproliferative disorders and chronic GVHD. Objective To characterize cutaneous eruptions arising from ibrutinib and highlight overlap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bda5464e52e9cca64e1f65e3d46f27ed
https://doi.org/10.1016/j.jaad.2019.12.031
https://doi.org/10.1016/j.jaad.2019.12.031
Autor:
Jeremy S. Abramson, Elizabeth Bengston, Robert Redd, Jeffrey A. Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal Shah, Eric Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann S. LaCasce, Celeste M. Bello
Publikováno v:
Blood Advances. 7:1130-1136
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e6d7122bf785841b263f83eb4c1cfc
https://doi.org/10.1182/bloodadvances.2022008420
https://doi.org/10.1182/bloodadvances.2022008420
Autor:
Christine E. Ryan, Danielle M. Brander, Paul M. Barr, Svitlana Tyekucheva, Liam R. Hackett, Mary C. Collins, Stacey M. Fernandes, Yue Ren, Yinglu Zhou, Mikaela M. McDonough, Heather A. Walker, Monica R. McEwan, Jeremy S. Abramson, Eric D. Jacobsen, Ann S. LaCasce, David C. Fisher, Jennifer R. Brown, Matthew S. Davids
Publikováno v:
Leukemia. 37:835-842
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcd9c6e487a35c7c8dba1553e3108c27
https://doi.org/10.1038/s41375-023-01830-2
https://doi.org/10.1038/s41375-023-01830-2